Truist Securities has maintained its Buy rating and $570.00 price target for Intuitive Surgical (NASDAQ: NASDAQ:ISRG).
The firm's analysis highlighted the company's third-quarter revenue and earnings per share (EPS) growth, which outpaced expectations. Intuitive Surgical saw a significant beat in U.S. system sales, including 110 of its Da Vinci model 5 systems, surpassing the estimated 78 units.
The quarter also experienced a stronger-than-anticipated increase in procedures, growing at 18% year-over-year compared to the consensus estimate of approximately 17%. This growth was partly attributed to an additional sales day in the quarter.
The margin outperformance contributed to a 26% year-over-year rise in EPS. The early success of the Da Vinci model 5 during its 'soft launch' phase was particularly noted as a positive indicator for the company's future performance. Truist Securities expressed increased confidence in the potential for estimate increases and accelerated growth into 2025, when a full launch of the new system is planned.
Intuitive Surgical's performance has cemented its status as a preferred large-cap stock within the medical technology sector, according to Truist Securities. The firm anticipates that Intuitive Surgical will continue to deliver mid-to-high teens revenue and EPS growth.
The company is also expected to sustain its substantial lead in the market for robotic surgical systems, which is still largely untapped and presents a significant opportunity for growth.
In other recent news, Intuitive Surgical has seen a series of significant developments. The medical technology company reported strong third-quarter results for 2024, with revenues of $2.038 billion, marking a 16.9% year-over-year increase, and an adjusted earnings per share (EPS) of $1.84.
These figures exceeded both BTIG's and consensus estimates. Intuitive Surgical's system sales and procedure volumes also surpassed Street expectations, with the latter showing an 18% year-over-year growth.
The company is expected to continue its growth trajectory, especially with its Da Vinci 5 (Dv5) surgical systems, as it gains regulatory approvals to enter new markets. Additionally, various firms, including Evercore ISI, Baird, Wells Fargo, BTIG, and RBC Capital Markets, have adjusted the company's stock target and ratings.
Intuitive Surgical has updated its guidance, now forecasting procedure growth of 16%-17% and a reduction in its operating expense growth to 10%-12%.
InvestingPro Insights
Intuitive Surgical's strong performance highlighted by Truist Securities is further supported by recent InvestingPro data. The company's market capitalization stands at an impressive $168.4 billion, reflecting its dominant position in the robotic surgical systems market. Intuitive Surgical's revenue growth of 13.62% over the last twelve months aligns with the analyst's positive outlook on the company's growth trajectory.
InvestingPro Tips indicate that Intuitive Surgical is trading near its 52-week high, with a substantial price uptick of 27.13% over the last six months. This momentum is consistent with the company's strong quarterly results and the market's enthusiasm for the Da Vinci model 5 system. Additionally, the company's high return over the last year, with a one-year price total return of 71.94%, underscores its strong market performance.
It's worth noting that Intuitive Surgical is trading at a high P/E ratio of 79.71, which may reflect investor expectations for continued growth. The company's robust financial health is evident in its liquid assets exceeding short-term obligations, providing a solid foundation for future investments and expansions.
For investors seeking a deeper understanding of Intuitive Surgical's potential, InvestingPro offers 15 additional tips, providing a comprehensive analysis of the company's financial position and market outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.